<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183701</url>
  </required_header>
  <id_info>
    <org_study_id>502.257</org_study_id>
    <nct_id>NCT02183701</nct_id>
  </id_info>
  <brief_title>Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension</brief_title>
  <official_title>A Prospective Randomised Open-Label Blinded Endpoint Trial Comparing Telmisartan 80 mg and Losartan 50 mg + Hydrochlorothiazide 12.5 mg (Fixed Dose Combination) in Patients With Mild-to-Moderate Essential Hypertension Using Ambulatory Blood Pressure Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The general aim and clinical objective of this trial is to determine the effect of&#xD;
      telmisartan 80 mg compared to losartan 50 mg + HCTZ (Hydrochlorothiazide) 12.5 mg on&#xD;
      reduction of blood pressure (BP) in patients with mild to moderate hypertension as assessed&#xD;
      by 24 hour Ambulatory Blood Pressure Monitoring (ABPM) and trough sitting BP cuff&#xD;
      measurements at the end of the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <primary_completion_date type="Actual">December 1998</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in 24-hour mean diastolic blood pressure measured by ABPM</measure>
    <time_frame>Baseline (Day 28 of run-in period) and day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hour mean systolic blood pressure measured by ABPM</measure>
    <time_frame>Baseline (Day 28 of run-in period) and day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic and diastolic blood pressures during other time periods during the 24-hour ABPM profile</measure>
    <time_frame>Baseline (Day 28 of run-in period) and day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline (Visit 2) in trough systolic and diastolic blood pressures measured by cuff sphygmomanometer</measure>
    <time_frame>Baseline (Day 28 of run-in period) and day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient with of adverse events</measure>
    <time_frame>up to 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in pulse rate</measure>
    <time_frame>Baseline (Day 28 of run-in period) and day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in physical examination</measure>
    <time_frame>Screening and day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory parameters</measure>
    <time_frame>Screening and day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Baseline (Day 29 of run-in period) and day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">715</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks placebo run-in, 6-weeks fixed dose period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan + Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 weeks placebo run-in, 6-weeks fixed dose period (Losartan 50 mg / HCTZ 12.5 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan + Hydrochlorothiazide</intervention_name>
    <arm_group_label>Losartan + Hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Losartan + Hydrochlorothiazide</arm_group_label>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild-to-moderate essential hypertension defined as a mean seated diastolic blood&#xD;
             pressure measurement of ≥ 95 mmHg measured by manual cuff sphygmomanometer, on Visit 2&#xD;
             of the four-week placebo run-in period (baseline)&#xD;
&#xD;
          -  Mean seated systolic blood pressure ≥ 140 mmHg, measured by manual cuff at baseline&#xD;
             (Visit 2)&#xD;
&#xD;
          -  A 24-hour mean diastolic blood pressure , measured by ABPM, of ≥ 85 mmHg evaluated at&#xD;
             baseline (Visit 3)&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Patient's written informed consent in accordance with GCP (Good Clinical Practice) and&#xD;
             local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-menopausal women (last menstruation ≤ 1 year prior to date of consent):&#xD;
&#xD;
               -  Who are not surgically sterile (hysterectomy, tubal ligation)&#xD;
&#xD;
               -  Who are NOT practising acceptable means of birth control or who do NOT plan to&#xD;
                  continue using an acceptable method throughout the trial. Acceptable methods of&#xD;
                  birth control include IUD (intrauterine device), oral, implantable or injectable&#xD;
                  contraceptives&#xD;
&#xD;
               -  Who have a positive urine pregnancy test&#xD;
&#xD;
               -  Who are nursing&#xD;
&#xD;
          -  Mean seated diastolic blood pressure (DBP) &gt; 114 mmHg or mean seated systolic BP &gt; 200&#xD;
             mmHg, by manual cuff&#xD;
&#xD;
          -  Any known hepatic and/or renal dysfunction as defined by the following laboratory&#xD;
             parameters:&#xD;
&#xD;
               -  SGPT (serum glutamate pyruvate transaminase) (ALT) or SGOT (serum glutamate&#xD;
                  oxaloacetate transaminase) (AST) greater than two times the upper limit of normal&#xD;
&#xD;
               -  Serum creatinine &gt; 1.8 mg/dl (or 159 µmol/l)&#xD;
&#xD;
          -  Clinically relevant hypokalemia&#xD;
&#xD;
          -  Known or suspected secondary hypertension&#xD;
&#xD;
          -  Known bilateral renal artery stenosis; renal artery stenosis in a solitary kidney;&#xD;
             post-renal transplant patients, presence of only one functioning kidney.&#xD;
&#xD;
          -  Congestive heart failure (CHF) (NYHA (New York Heart Association) class CHF III-IV)&#xD;
&#xD;
          -  Unstable angina within the past 3 months; stable angina where a change in nitrate&#xD;
             therapy (dose or frequency) during the run-in period was required&#xD;
&#xD;
          -  Stroke within the past 6 months prior to start of run-in period&#xD;
&#xD;
          -  Myocardial infarction or cardiac surgery within the past 3 months prior to start of&#xD;
             run-in period&#xD;
&#xD;
          -  PTCA (percutaneous transluminal coronary angioplasty) within the past 3 months prior&#xD;
             to start of run-in period&#xD;
&#xD;
          -  Previous history of angioedema&#xD;
&#xD;
          -  Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other&#xD;
             clinically relevant cardiac arrhythmias as determined by the investigator&#xD;
&#xD;
          -  Hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the&#xD;
             aortic or mitral valve&#xD;
&#xD;
          -  Patients with unstable insulin-dependent diabetes mellitus (risk of hypoglycemia or&#xD;
             HbA1c ≥ 10 % in history within 6 months prior to start of run-in period)&#xD;
&#xD;
          -  Known drug or alcohol dependency within the past 6 months period prior to start of&#xD;
             run-in period&#xD;
&#xD;
          -  Concomitant administration of medications known to affect blood pressure, except&#xD;
             medications allowed by the protocol&#xD;
&#xD;
          -  Patients receiving any investigational therapy within one month of signing the&#xD;
             informed consent form&#xD;
&#xD;
          -  Known hypersensitivity to any component of the formulations&#xD;
&#xD;
          -  Any clinical condition which, in the opinion of the investigator, would not allow safe&#xD;
             completion of the protocol and safe administration of trial medication&#xD;
&#xD;
          -  Concomitant use of lithium or cholestyramine or colestipol resins (potential drug&#xD;
             interactions with HCTZ)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.257_U99-1695.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 7, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

